JP2024520577A5 - - Google Patents

Info

Publication number
JP2024520577A5
JP2024520577A5 JP2023573662A JP2023573662A JP2024520577A5 JP 2024520577 A5 JP2024520577 A5 JP 2024520577A5 JP 2023573662 A JP2023573662 A JP 2023573662A JP 2023573662 A JP2023573662 A JP 2023573662A JP 2024520577 A5 JP2024520577 A5 JP 2024520577A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
nos
acid sequences
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/064703 external-priority patent/WO2022253805A1/en
Publication of JP2024520577A publication Critical patent/JP2024520577A/ja
Publication of JP2024520577A5 publication Critical patent/JP2024520577A5/ja
Pending legal-status Critical Current

Links

JP2023573662A 2021-06-01 2022-05-31 抗nkg2a抗体及び組成物 Pending JP2024520577A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
US63/195,470 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (2)

Publication Number Publication Date
JP2024520577A JP2024520577A (ja) 2024-05-24
JP2024520577A5 true JP2024520577A5 (cg-RX-API-DMAC7.html) 2025-06-06

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573662A Pending JP2024520577A (ja) 2021-06-01 2022-05-31 抗nkg2a抗体及び組成物

Country Status (17)

Country Link
US (2) US12012450B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347651A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520577A (cg-RX-API-DMAC7.html)
KR (1) KR20240016991A (cg-RX-API-DMAC7.html)
CN (1) CN117460748A (cg-RX-API-DMAC7.html)
AR (1) AR126001A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022286617A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222040A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003562A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015982A2 (cg-RX-API-DMAC7.html)
IL (1) IL308695A (cg-RX-API-DMAC7.html)
MX (1) MX2023014320A (cg-RX-API-DMAC7.html)
PE (1) PE20240372A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023553123A1 (cg-RX-API-DMAC7.html)
TW (1) TW202313683A (cg-RX-API-DMAC7.html)
WO (1) WO2022253805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4644422A1 (en) * 2022-12-28 2025-11-05 BioRay Pharmaceutical Co., Ltd. Anti-nkg2a antibody and use thereof
CN121358774A (zh) * 2023-06-21 2026-01-16 科望(苏州)生物医药科技有限公司 与nkg2a结合的抗体或抗原结合片段及其用途
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
AU2015316993B2 (en) * 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) * 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN116693685A (zh) * 2016-04-12 2023-09-05 法国施维雅药厂 抗tim-3抗体及组合物
EP3878869A4 (en) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.

Similar Documents

Publication Publication Date Title
CN115551888B (zh) 抗cd73抗体及其用途
JP2021511811A5 (cg-RX-API-DMAC7.html)
CN109384846B (zh) 能够结合tigit的抗体或其抗原结合片段及用途
CA2738782C (en) Anti cxcr4 antibodies and their use for the treatment of cancer
US9249223B2 (en) Humanized anti CXCR4 antibodies for the treatment of cancer
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2021524244A5 (cg-RX-API-DMAC7.html)
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2022527635A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
JP2021508469A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
HRP20211820T1 (hr) Anti-tim-3 protutijela i pripravci
JP2015508280A5 (cg-RX-API-DMAC7.html)
JP2022548764A5 (cg-RX-API-DMAC7.html)
TW201026325A (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
JP2021528047A5 (cg-RX-API-DMAC7.html)
CA2670039A1 (en) Novel antiproliferation antibodies
CN112830969B (zh) 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒
JP2023522630A5 (cg-RX-API-DMAC7.html)
TW202221035A (zh) 抗ilt2抗體及其用途
JP2022547416A5 (cg-RX-API-DMAC7.html)
CN112094348B (zh) 抗人Tim3抗体或其功能性片段及其应用
IL312060A (en) Bispecific CD16A binders
RU2017134042A (ru) ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ